Literature DB >> 12018471

Nosocomial pneumonia: a cost-of-illness analysis.

E S Dietrich1, M Demmler, G Schulgen, K Fekec, O Mast, K Pelz, F D Daschner.   

Abstract

BACKGROUND: We investigated incremental cost of nosocomial pneumonia (NP) from the perspective of a hospital and health insurance funds. PATIENTS AND METHODS: The incremental cost was determined by calculating total costs for pneumonia patients and controls using prospective and retrospective matched-pairs analysis with 29 and 37 matched pairs, respectively.
RESULTS: Compared to controls, patients who developed pneumonia had to be on artificial ventilation 5 days longer, needed markedly more intensive care with 6.55 additional days in intensive care. Excess cost per pneumonia patient amounted to DM 14,606 (95% CI: DM 5,285-23,927) from the hospital's perspective and to DM 7,988 (95% CI: DM 5,281-10,894) according to statutory insurance charges. According to the retrospective anaLysis carried out on the neurosurgical and neurological intensive care wards, pneumonia patients were ventiLated 5 days longer than patients without pneumonia, needed more intensive care over 30 days and had an additional 14.03 days of intensive care and 10.14 more days in hospital. Excess cost per patient was DM 29,610 (95% CI: DM 23,054-36,174) from the hospitals perspective and DM 18,000 (95% CI: 14,885-21,020) according to the statutory insurance criteria.
CONCLUSION: The study gives insight into the structure of incremental cost caused by NP and shows that based on a conservative cost calculation the incremental cost per NP patient is higher for the hospital than for health insurance funds which indicates a significant financial deficit for the hospital. Antibiotics and microbiology together only contribute 6.8% to incremental cost. Therefore in a cost saving initiative their close relationship to length of hospitalization must be considered.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12018471     DOI: 10.1007/s15010-002-1083-8

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  12 in total

1.  Cost of infectious diseases.

Authors:  C Ruef
Journal:  Infection       Date:  2002-04       Impact factor: 3.553

Review 2.  Linezolid: a pharmacoeconomic review of its use in serious Gram-positive infections.

Authors:  Greg L Plosker; David P Figgitt
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

Review 3.  Cost-of-illness studies : a review of current methods.

Authors:  Ebere Akobundu; Jing Ju; Lisa Blatt; C Daniel Mullins
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

Review 4.  Costs of hospital-acquired infection and transferability of the estimates: a systematic review.

Authors:  H Fukuda; J Lee; Y Imanaka
Journal:  Infection       Date:  2011-03-22       Impact factor: 3.553

5.  Examination with next-generation sequencing technology of the bacterial microbiota in bronchoalveolar lavage samples after traumatic injury.

Authors:  Ryan M Huebinger; Ming-Mei Liu; Scot E Dowd; Fernando A Rivera-Chavez; John Boynton; Curtis Carey; Kenneth Hawkins; Christian T Minshall; Steven E Wolf; Joseph P Minei; Robert C Barber
Journal:  Surg Infect (Larchmt)       Date:  2013-05-06       Impact factor: 2.150

6.  Cost-effectiveness of linezolid vs vancomycin in suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia in Germany.

Authors:  E De Cock; W A Krueger; S Sorensen; T Baker; J Hardewig; S Duttagupta; E Müller; A Piecyk; E Reisinger; A Resch
Journal:  Infection       Date:  2009-03-09       Impact factor: 3.553

Review 7.  Epidemiology and economic impact of meticillin-resistant Staphylococcus aureus: review and analysis of the literature.

Authors:  Andrew F Shorr
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

Review 8.  Recent advances in dead cell clearance during acute lung injury and repair.

Authors:  Patrick M Noone; Sekhar P Reddy
Journal:  Fac Rev       Date:  2021-03-30

9.  Long-term medical utilization following ventilator-associated pneumonia in acute stroke and traumatic brain injury patients: a case-control study.

Authors:  Chih-Chieh Yang; Nai-Ching Shih; Wen-Chiung Chang; San-Kuei Huang; Ching-Wen Chien
Journal:  BMC Health Serv Res       Date:  2011-10-31       Impact factor: 2.655

10.  The economic burden of patient safety targets in acute care: a systematic review.

Authors:  Nicole Mittmann; Marika Koo; Nick Daneman; Andrew McDonald; Michael Baker; Anne Matlow; Murray Krahn; Kaveh G Shojania; Edward Etchells
Journal:  Drug Healthc Patient Saf       Date:  2012-10-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.